A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Affiliations

• ¹ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
• ² Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
• ³ Department of Internal Medicine, Lankenau Medical Center, Wynnewood, PA.
• ⁴ Roswell Park Cancer Institute, Buffalo, NY.
• ⁵ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
• ⁶ Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.
• ⁷ Department of Hematology and Medical Oncology, George Washington University Cancer Center, Washington, DC; and.
• ⁸ Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH.